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Nucleolar Sequestration of RelA (p65) Regulates NF-B-Driven
Transcription and Apoptosis
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The molecular mechanisms that regulate nuclear NF-B to determine whether the stimulation of this
pathway has a pro- or antiapoptotic effect on cells have yet to be fully defined. Nuclear compartmentalization
is increasingly recognized as an important mechanism for regulating the activity of transcription-related
proteins and modulating cell growth and death. We have investigated whether such compartmentalization
serves as a mechanism for regulating NF-B transcriptional activity. We demonstrate that the RelA component
of NF-B is sequestered in the nucleolus in response to the proapoptotic NF-B stimuli aspirin, serum
withdrawal, and UV-C radiation. In contrast, RelA is excluded from the nucleolus in response to the cytokines
tumor necrosis factor and TRAIL. We identify an N-terminal motif of RelA that is essential for the nucleolar
localization of the protein and show that deleting this motif inhibits the translocation of RelA from the
nucleoplasm to the nucleolus. We demonstrate that the nucleolar accumulation of RelA is paralleled by a
decrease in basal levels of NF-B transcriptional activity and by apoptosis. Furthermore, we show that the
retention of RelA in the nucleoplasm inhibits this decrease in NF-B-driven transcription and blocks apoptosis
induced by aspirin and UV-C radiation. This work identifies a novel cellular mechanism for regulating
NF-B-driven transcription and apoptosis, involving the nucleolar sequestration of a key NF-B subunit.
These data contribute to the understanding of the complexities of NF-B function and have considerable
relevance to cancer prevention and therapy.
NF-B is a ubiquitously expressed, inducible transcription
factor that regulates the transcription of a diverse array of
genes (1, 30). There are five known members of the mamma-
lian NF-B/Rel family which can dimerize through their Rel
homology domain to form a variety of different transcription
factor complexes (45). Although all members of the NF-B
family can bind DNA, only RelA, c-rel, and RelB have trans-
activating functions. The most abundant form of NF-B is a
heterodimer of the p50 and RelA polypeptides. In most cell
types, this complex exists in the cytoplasm bound to a family of
IB inhibitory proteins. Following cellular stimulation by spe-
cific inducers, IB is phosphorylated by the IB kinase (IKK)
complex at serines 32 and 36 and then degraded by the 26S
proteosome (20). Subsequently, NF-B translocates to the nu-
cleus, where it regulates the transcription of target genes.
It is now well established that NF-B plays an essential role
in controlling cellular growth properties and apoptotic cell
death (21, 31). However, the cellular consequences of activat-
ing the NF-B pathway are complex, since the nuclear trans-
location of NF-B can have both pro- and antiapoptotic effects
(14). For instance, the induction of the NF-B pathway by
cytokines such as tumor necrosis factor (TNF) results in the
nuclear translocation of NF-B complexes that are antiapo-
ptotic and promote cell growth (2, 46). In keeping with an
antiapoptotic role for NF-B, inappropriate activation of the
NF-B pathway has been shown to contribute to tumor for-
mation in a number of cancer types (21), while increased DNA
binding of NF-B is associated with tumor resistance to che-
motherapy (44). In contrast, when stimulated by agents such as
UV radiation and serum withdrawal, the nuclear translocation
of NF-B can promote cell death (5, 25, 39). In this lab, we are
interested in the mechanism by which aspirin mediates the
apoptosis of colon cancer cells. In previously published work,
we reported that in the absence of additional cytokines, aspirin
activates the NF-B pathway and that NF-B complexes in-
duced by aspirin are also proapoptotic (13, 42). Consistent with
the notion of differing cellular responses to NF-B nuclear
translocation, NF-B can activate the transcription of both
proapoptotic and antiapoptotic genes (30). However, the
mechanisms that regulate nuclear NF-B to determine the
spectrum of genes which are activated/repressed by a specific
signal are complex, and the downstream effects on cell growth
and death have yet to be fully defined (8).
The compartmentalization of transcription-associated pro-
teins within nuclear bodies is increasingly recognized as an
important mechanism for regulating gene expression, cell pro-
liferation, and apoptosis (3, 7). For example, the activity of the
p53 tumor suppressor gene is regulated by the nucleolar se-
questration of its negative regulator, MDM2 (37, 47), and
c-myc-induced progression through the cell cycle is inhibited by
the sequestration of the protein in the nucleolus (10). In terms
of NF-B, the nucleolar protein p14ARF has recently been
shown to interact with RelA and inhibit NF-B-driven tran-
scription (32), while in two recent screens for NF-B-interact-
ing partners, the predominant proteins identified were the
nucleolar proteins NFBP (43) and nucleophosmin/B23 (12).
Furthermore, the NF-B regulators NIK (NF-B-inducing ki-
nase) (4) and NRF (NF-B repressing factor) (29) have very
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recently been shown to function through nucleolar shuttling.
However, the regulation of NF-B transcriptional activity and
apoptosis by the nuclear organization of NF-B proteins has
yet to be examined.
Here we report that the RelA component of NF-B trans-
locates to the nucleolus following induction by the proapo-
ptotic NF-B stimuli aspirin, serum deprivation, and UV-C
radiation. We identify a nucleolar localization signal (NoLS) at
the N terminus of RelA and, using a dominant-negative mu-
tant of RelA with a deletion of this nucleolar localization
motif, we demonstrate that the nucleolar sequestration of
RelA causes a reduction in basal levels of NF-B transcrip-
tional activity and apoptosis. These findings suggest a novel
mechanism to regulate nuclear NF-B activity and apoptosis
involving the nucleolar compartmentalization of RelA.
MATERIALS AND METHODS
Cell culture and reagents. SW480 and HRT18 colon cancer cell lines are
available from the American/European Type Culture Collections, and immor-
talized rela null mouse embryo fibroblasts (MEFs) were kindly provided by R. T.
Hay (University of St. Andrews). SW480 cells were maintained in L-15 medium,
HRT18 in RPMI 1640, and MEFs in Dulbecco modified Eagle medium. All
media were supplied by Gibco BRL and supplemented with penicillin (100
IU/ml), streptomycin (100 g/ml), and 10% fetal calf serum (FCS). The gener-
ation of HRT18 cells expressing superrepressor IB (IBSR or IBs32-36) has
been described previously (42). IBSR-expressing clones were subcultured in
RPMI under Geneticin (Gibco BRL, Paisley, United Kingdom) selection and
then grown in the absence of Geneticin during aspirin treatment. Aspirin
(Sigma) was solubilized in water using 10 N NaOH, and then the pH was
adjusted to 7.0. For aspirin treatment, cells were plated at a density of 1  105
per 50-ml flask, grown until 60 to 80% confluent, and then treated continuously
with aspirin in either 0.5% FCS (SW480 and HRT 18 cells) or 10% FCS (MEFs)
for a further 16 h or 72 h or as specified below. To study the effects of inhibitors
on the response to aspirin, cells were preincubated in low-serum medium con-
taining 50 M MG132 (Calbiochem), 20 nM leptomycin B, 200 M pyrrolidine
dithiocarbamate (PDTC; Sigma), 0.5 g/ml actinomycin D (Sigma), or 10 M
cycloheximide (Sigma) for 1 h prior to the addition of aspirin (5 mM) for a
further 16 h. Cells were treated with TNF and TRAIL (R&D Systems) in
low-serum medium as described above for the times specified below. For serum-
deprivation experiments, cells were grown overnight in medium containing 10%
serum. This medium was then replaced with either 10% or 0% FCS-containing
medium, and cells were incubated for a further 96 h. For UV-C irradiation, cells
(seeded in six-well plates) were washed in phosphate-buffered saline, exposed to
UV-C irradiation (40 J/m2) using a Stratalinker instrument (Stratagene), and
then recovered in original medium for the times specified below.
Plasmids. The 3enhancer CONA (3x B ConA-Luc) and human immuno-
deficiency virus (HIV)-long terminal repeat (LTR) wild-type (WT) and B-
deleted reporter constructs were supplied by R. T. Hay (University of St. An-
drews) and have been described elsewhere (34). The pCMV--galactosidase
plasmid is commercially available (Promega). The green fluorescent protein
(GFP)-RelA expression construct was a kind gift from E. Qwarnstrom (Univer-
sity of Sheffield) (6). To generate GFP-tagged deletion mutants, RelA fragments
corresponding to amino acids (aa) 1 to 311, 290 to 511, 105 to 511, and 50 to 511
were PCR amplified using GFP-RelA as a template. PCR fragments were cloned
in fusion with GFP in the pEGFP-C1 (Clonetech) vector. The QuikChange
site-directed mutagenesis kit (Stratagene), along with primers made using
QuikChange primer design, was used to generate the RelA construct with a
deletion of amino acids 27 to 30 (RelA27-30) and the K28/R mutation. The
sequences of all constructs were confirmed by the sequencing of plasmid DNA
on an ABI3700 genetic analyzer.
Antibodies. The following primary antibodies were used: sheep polyclonal
anti-IB (gift from R. T. Hay [University of St. Andrews]), sheep polyclonal
anti-Cu/ZnSOD (The Binding Site), rabbit polyclonal anti-p65 (Santa Cruz),
mouse monoclonal anti-p65 (Santa Cruz), mouse monoclonal anti-nucleolin
(Santa Cruz), goat polyclonal anti-fibrillarin (Santa Cruz), mouse monoclonal
anti-Ki-67 (Santa Cruz), mouse monoclonal anti-pk TAG (TCS Cellworks),
rabbit polyclonal anti-GFP (Santa Cruz), and goat polyclonal anti-caspase-3
(R&D Systems).
Transfections and reporter assays. For the analysis of NF-B-driven transcrip-
tion, cells were transfected with the indicated reporter plasmids using Lipofectin
(SW480 and HRT18 cells) or Lipofectamine 2000 (MEFs), as described by the
manufacturer (Gibco BRL). Cells were grown for 24 h and then treated with
aspirin (0 to 10 mM) for the times specified below. Luciferase and -galactosi-
dase activities were measured in cell extracts using a luciferase reporter assay kit
(Promega) and a -galactosidase assay kit (Promega) as per the manufacturer’s
instructions. The relative luciferase activity was calculated as the units of lucif-
erase activity per unit of -galactosidase activity. All results shown are the means
of triplicates of at least three independent experiments. To analyze the effects of
aspirin and UV-C radiation on the cellular localization of wild-type and mutant
RelA, SW480 cells were transfected with GFP-RelA expression constructs as
described above. Transfected cells were recovered for 24 h and then treated with
aspirin for a further 16 h or recovered for 8 h after UV-C irradiation (40 J/m2).
The localization of GFP-tagged proteins was analyzed in adherent cells using an
Axiovert 100 inverted microscope (Zeiss) at an excitation wavelength of 488 nm.
Images were captured and processed using IPLab 3.6. To determine the effects
of N-terminal deletions of RelA on NF-B-driven transcription in SW480 cells,
cells were transfected with either GFP-RelA or RelA27-30 along with 3xB
ConA-luc as described above. The total adherent cell population was harvested,
and then cells expressing GFP-tagged protein were isolated from nonexpressing
cells using a fluorescence-activated cell sorter (Becton Dickinson). Luciferase
assays were performed on lysates from GFP-expressing cells, and the relative
luciferase activity was calculated as the level of luciferase activity per GFP-tagged
cell (as determined during cell sorting).
Western blot analysis. Following aspirin treatment, cytoplasmic and nuclear
extracts were prepared from adherent cells as previously described (35, 42). To
examine the expression levels of GFP-tagged RelA proteins, whole-cell extracts
(using lysis buffer consisting of 50 mM Tris-HCl [pH 7.4], 250 mM NaCl, 0.5%
NP-40, 10% glycerol, 0.1 mM EDTA, 0.5 mM dithiothreitol, protease inhibitors)
were prepared from transfected cells. Bradford assays (Bio-Rad) were used to
measure protein content. Extracts (20 g) were resolved on 10% sodium dodecyl
sulfate-polyacrylamide gels, and immunoblotting was performed by standard
procedures. Membranes were probed with anti-Cu/ZnSOD or anti-actin as a
control for protein loading. Electrophoretic mobility shift assays (EMSAs) were
performed on nuclear extracts as previously described by us (42).
Immunocytochemical staining. SW480 cells were grown on sterilized cover-
slips until 60 to 80% confluent and then treated with aspirin in low-serum (0.5%
FCS) medium as specified below. Cells were fixed in 1:1 methanol:acetone at
20°C for 20 min, and then immunocytochemistry was performed using standard
procedures. Primary antibodies were diluted in 1.5% donkey serum as follows:
p65 (rabbit polyclonal or mouse monoclonal) (1:100), nucleolin (C23) (1:100),
fibrillarin (1:100), and Ki-67(1:50). Coverslips were mounted in Vectastain (Vec-
tor Laboratories) containing DAPI (4	,6	-diamido-2-phenylindole) and cells an-
alyzed using fluorescent microscopy. The permeabilization of cells prior to fix-
ation was carried out as previously described (22a). Fluorescent microscopy was
performed with a Zeiss Axioplan microscope with a 63 Plan Neofluor objective
and a Chroma 83000 filter set. Each channel was recorded independently, and
pseudocolor images were superimposed. Images were captured using in-house
scripts written for IPLab Spectrum 3.6.
Isolation of nucleoli. Nucleoli were isolated from 6  108 SW480 cells as
described elsewhere (http://www.lamondlab.com/f5nucleolarprotocol.htm). Nu-
cleoli were resuspended in phosphate-buffered saline, and the protein contents
of all cell fractions were analyzed using Bradford assays (Bio-Rad). All steps
were carried out at 4°C. Western blot analysis was performed as described above.
Viability and apoptosis assays. Staining for cell surface phosphatidylserine was
used as a marker for apoptosis and was carried out using an annexin V-fluores-
cein isothiocyanate (FITC) apoptosis detection kit (Oncogene Research Prod-
ucts) as per the manufacturer’s instructions. The percentage of apoptotic cells
within the cell population was determined by microscopy. At least 250 cells from
multiple fields of view were counted for each sample. To analyze the effects of
the GFP-RelA deletion mutants on the modulation of cell viability, cells were
transiently transfected with the GFP-tagged expression constructs and then stim-
ulated as described above. Phase-contrast images of randomly selected fields of
adherent cells were captured using an Axiovert 100 inverted microscope (Zeiss),
and then the total number of cells was determined using hemocytometric counts.
To examine the effects of RelA cellular distribution on aspirin- and UV-C-
induced apoptosis, cells were transfected with the GFP-RelA wild-type and
deletion mutants and treated as described above. Apoptotic cells were detected
using an annexin V-biotin kit (Oncogene) with a streptavidin-Texas Red conju-
gate (Oncogene) as per the manufacturer’s instructions. The numbers of non-
apoptotic (bright-field channel), apoptotic (Texas Red channel), transfected
(FITC channel), and transfected apoptotic cells were determined by microscopy,
5986 STARK AND DUNLOP MOL. CELL. BIOL.
 o
n
 M
arch 27, 2014 by guest
http://m
cb.asm
.org/
D
ow
nloaded from
 
FIG. 1. RelA accumulates in distinct nuclear bodies following aspirin treatment. (A) Immunomicrograph (magnification, 63) showing the
subcellular distributions of RelA in control and aspirin-treated (0.5 to 2 mM for 72 h or 3 to 5 mM for 16 h) SW480 cells. Nuclear accumulations
of RelA are observed at pharmacologically relevant doses. Nuclei are stained with DAPI. Bars, 10 m. (B) SW480 cells were transiently transfected
with a GFP-RelA expression vector 24 h prior to aspirin (0 [] or 5 [] mM for 16 h) stimulation. Fluorescent and phase-contrast images
(magnification, 40) of adherent cells were captured using an Axiovert 100 inverted microscope. Arrows indicate nucleoli.
VOL. 25, 2005 NUCLEOLAR SEQUESTRATION OF RelA INDUCES APOPTOSIS 5987
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FIG. 2. RelA localizes in the nucleolus in response to aspirin. (A) Immunocytochemical staining (magnification, 63) showing that RelA
colocalizes with the nucleolar proteins nucleolin and fibrillarin, but not with Ki67, when induced by aspirin. SW480 cells were unstimulated
(control) or stimulated with aspirin (5 mM, 16 h) and then fixed, and immunocytochemistry was performed using the specified antibodies. DNA
is stained by DAPI. Bars, 10 m. (B) RelA is held within nucleolar bodies after aspirin treatment. The immunomicrographs (magnification, 63)
show the cellular localization of RelA in aspirin (Asp.)-treated (5 mM, 16 h) SW480 cells with () and without () permeabilization (Perm.) prior
to fixation and immunocytochemical analysis. Nucleolin (C23) staining depicts nucleoli. Merged image shows DAPI-stained DNA (blue).
(C) Aspirin induces a decrease in nucleoplasmic and an increase in nucleolar levels of RelA. Nontreated and aspirin (Asp.)-treated (5 mM, 16 h)
SW480 cells were fractionated using sucrose gradients. Western blot analysis was then performed on protein extracted from the specified cell
fractions using anti-RelA followed by anti-nucleolin (C23) antibodies.
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and the percentages of transfected cells, apoptotic cells, and transfected apopto-
tic cells within the cell population were calculated. At least 250 transfected cells
were examined for annexin V binding in each sample. All results presented are
the means of at least three experiments 
 standard errors (SE).
RESULTS
Nucleolar localization of RelA. We set out to determine
whether NF-B effects on cell growth and death were regu-
lated at the nuclear level by the compartmentalization of
NF-B proteins. We previously reported that the stimulation
of the NF-B pathway by aspirin induces nuclear translocation
of NF-B complexes that promote apoptosis (13, 42), and so
we focused on aspirin as a proapoptotic NF-B stimulus. Using
immunocytochemical analysis, we first examined the sub-
nuclear distribution of endogenous NF-B proteins in aspirin-
treated SW480 colon cancer cells. Our previous studies indi-
cated that the NF-B complex induced by aspirin consisted
predominantly of RelA (42), and so we examined this critical
component of NF-B. We found that prior to induction by
aspirin, RelA was present mainly in the cytoplasm, with a small
amount of nucleoplasmic staining (Fig. 1A). However, in re-
sponse to aspirin, RelA accumulated in the nucleoplasm and,
more interestingly, became compartmentalized into distinct
nuclear bodies (Fig. 1A). Cells showing nuclear foci of RelA
were observed at aspirin concentrations as low as 500 M,
which is comparable to the salicylate levels that we measured
in plasma samples from subjects given standard analgesic doses
of aspirin (42). Furthermore, the number of cells showing
these foci increased in a dose-dependent manner (Fig. 1A and
data not shown). To confirm that the observed nuclear accu-
mulations of RelA were not an artifact of the staining proce-
dure, SW480 cells that had been transfected with a GFP-RelA
expression construct were analyzed. Using live-cell imaging, we
found that the GFP-tagged RelA showed the same subcellular
localization that we demonstrated for endogenous protein
(Fig. 1B). GFP-tagged RelA was localized mainly to the cyto-
plasm and, to a much lesser degree, in the nucleoplasm, prior
to aspirin exposure. However, in response to aspirin, there was
a dramatic relocalization of RelA from the cytoplasm/nucleo-
plasm to distinct subnuclear bodies. Aspirin had no effect on
the distribution of GFP alone (see below). These data establish
that RelA accumulates in distinct subnuclear bodies in re-
sponse to aspirin.
The eukaryotic nucleus contains a number of well-defined
FIG. 3. Specificity of stimuli causing nucleolar localization of RelA.
(A) SW480 cells were unstimulated (control) or stimulated with TNF
(10 ng/ml, 1 h) and then fixed, and immunocytochemistry was per-
formed using specified antibodies. Nucleoli are stained with nucleolin.
(B) Immunocytochemistry was performed on SW480 cells either un-
treated or treated with TRAIL (10 ng/ml) for 16 h. Fibrillarin was used
to identify nucleoli. (C) SW480 cells were seeded in medium contain-
ing 10% serum and grown for 16 h. Medium was then replaced by fresh
medium containing either 10% or 0% serum, and cells were grown for
a further 96 h. Following fixation, immunocytochemistry was per-
formed using antibodies to RelA and nucleolin as described above.
(D) Immunocytochemistry, using anti-RelA and anti-nucleolin anti-
bodies, was performed on SW480 cells 5 h after mock or UV-C (40
J/m2) irradiation. In all merged panels, DNA is stained by DAPI and
appears blue.
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structures, including splicing speckles, Cajal bodies, chromatin
territories, and nucleoli (3, 7, 24). Since the nuclear foci of
RelA colocalized with dense, refractile nuclear bodies, as
shown by phase microscopy (Fig. 1B), and with areas unstained
by DAPI (Fig. 1A), as shown by immunocytochemical analysis,
we considered it likely that the RelA was accumulating within
nucleoli. This was confirmed by immunocytochemical analysis
demonstrating that aspirin-induced nuclear RelA colocalizes
with the nucleolar proteins nucleolin (C23) and fibrillarin
(Fig. 2A). Ki-67 is a proliferation marker whose presence in
the nucleolus is cell cycle dependent (11). We found that Ki-67
was mainly nucleoplasmic in aspirin-treated cells and showed
minimal colocalization with RelA (Fig. 2A), suggesting that
the nucleolar accumulation of RelA is a protein-specific event
and not a general consequence of changes in proliferation. The
permeabilization of cells prior to immunocytochemical analysis
confirmed that RelA was bound within the nucleolus after
aspirin treatment (Fig. 2B).
To further confirm that aspirin mediates the nucleolar ac-
cumulation of RelA, nucleoli were purified from untreated and
aspirin-treated SW480 cells. Western blot analysis of cell frac-
tions revealed substantially increased levels of RelA in nucleoli
from aspirin-treated cells compared to nucleoli purified from
untreated controls (Fig. 2C). Furthermore, the increase in
nucleolar RelA was associated with decreased levels of the
protein in the cytoplasm and, importantly, in the nucleoplasm
(Fig. 2C). Aspirin had no significant effect on nucleolar or
nucleoplasmic levels of nucleolin (C23) (Fig. 2C). The purity of
isolated nucleoli was confirmed using lamin B (a nuclear pro-
tein that does not accumulate in nucleoli), which showed min-
imal staining in the purified nucleolar fractions (data not
shown). Taken together, these cell-imaging and molecular
studies confirm that RelA localizes to the nucleolus in re-
sponse to aspirin.
Specificity of stimuli causing nucleolar localization of RelA.
We wished to determine whether other NF-B stimuli, partic-
ularly those known to be proapoptotic, had effects similar to
that of aspirin on the nuclear distribution of RelA. Using
immunocytochemical analysis, we examined the distribution of
RelA in response to the proapoptotic NF-B stimuli serum
withdrawal, UV-C, and TRAIL and to the antiapoptotic signal
TNF. Following exposure to TNF and TRAIL, we found that
RelA was concentrated within the nucleoplasm as expected,
but there was no detectable nucleolar staining for RelA (Fig.
3A and B). In contrast, serum deprivation (27) and UV-C (40
J/m2) radiation (22) resulted in RelA colocalization with the
nucleolar proteins nucleolin and fibrillarin, thereby confirming
that RelA also localizes to the nucleolus following exposure to
these atypical activators of the NF-B pathway. These data
demonstrate clear differences in the nuclear distributions of
RelA, depending upon the nature of the inducer. The data also
suggest the intriguing possibility that the nucleolar sequestra-
tion of RelA is a general mechanism for regulating NF-B
activity and apoptosis.
Mode of accumulation of RelA within nucleoli. To begin to
elucidate the functional significance of these observations, we
wished to understand the mechanism by which RelA is tar-
geted to the nucleolus. We are particularly interested in the
proapoptotic effects of aspirin and so used this agent as a
model system for examining nucleolar targeting of RelA.
It is now recognized that RelA shuttles continuously be-
tween the cytoplasm and the nucleus of resting cells, utilizing
the Crm1p nuclear export pathway (33). Since this export path-
way is also used to export ribosomes from the nucleolus to the
cytoplasm, we speculated that RelA exits the nucleus via the
nucleolus and that nucleolar accumulation of RelA is caused
by the disruption of Crm1p-mediated nuclear export. We pos-
tulated that if this were the case, then nucleolar accumulation
of RelA would be apparent in the presence of the Crm1p
inhibitor, leptomycin B. However, we found that in the pres-
ence of leptomycin B, RelA accumulated in the nucleoplasm
and was excluded from nucleoli (Fig. 4A). Furthermore, lep-
tomycin B had no effect on aspirin-induced nucleolar accumu-
lation of RelA (Fig. 4A). These data indicate that the nucleolar
localization of RelA is independent of Crm1p-mediated nu-
clear export.
Next, we wished to establish whether translocation from the
cytoplasm to the nucleus is required for the nucleolar accumu-
lation of RelA or whether it is the nucleoplasmic pool of RelA
that is targeted to translocate to the nucleolus. We initially
treated SW480 cells with aspirin in the presence of the inhib-
itor of IB phosphorylation and degradation, PDTC. We
found that PDTC blocked both aspirin-induced degradation of
IB (data not shown) and the nucleolar accumulation of RelA
(Fig. 4A). This was further confirmed using HRT18 colon
cancer cells which we engineered to constitutively express a
superrepressor form of IB (IBSR). This IB is mutated at
the critical serine phosphorylation sites (S32/S36) and is resis-
tant to aspirin-induced phosphorylation and degradation (42).
Clones IBSR1 and IBSR28 express levels of the mutant IB
protein that inhibit aspirin-induced (42) and TNF-induced (51)
nuclear translocation of NF-B. We found that IBSR1 and 28
clones showed nucleoplasmic staining for RelA prior to aspirin
treatment (Fig. 4B). This would suggest that the basal turnover
of NF-B in these cells is independent of IB 32/36 phosphor-
ylation (36). However, the IBSR clones showed no nucleolar
FIG. 4. Mode of nucleolar accumulation of RelA. (A) Immunocytochemical staining showing localization of RelA in SW480 cells treated with
aspirin (Asp; 5 mM for 16 h) in the presence () and absence () of the inhibitor of nuclear export, leptomycin B (LMB), and of the inhibitor
of IB degradation, PDTC. Nucleoli are stained with nucleolin (C23), and nuclei are stained with DAPI. (B) Expression of superrepressor IB
inhibits nucleolar accumulation of RelA. Parental HRT18 cells and two clones expressing mutant IB, resistant to aspirin-induced degradation
(IB SR1 and SR28) were untreated (control) or treated with 5 mM aspirin for 16 h. The cellular localization of RelA was determined using
immunocytochemical staining. (C) Nucleolar accumulation of RelA requires de novo protein synthesis. The immunomicrographs show the cellular
localization of RelA and nucleolin following treatment with aspirin (Asp.) (5 mM, 16 h) in the presence and absence of 0.5 g/ml actinomycin D
(ActD) or 10M cycloheximide (CHX). The arrow indicates the exclusion of RelA from remaining nucleoli in actinomycin D-treated cells.
(D) Immunomicrographs showing the cellular localization of RelA in cells exposed to 0% serum for 96 h in the presence or absence of actinomycin
D (ActD) or cycloheximide (CHX) as described above. DNA is stained by DAPI and appears blue in the merged panels. Bars, 10 m.
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accumulation of RelA upon the induction of the NF-B path-
way by aspirin (Fig. 4B). In contrast, aspirin-mediated nucle-
olar accumulation of RelA was observed in parental HRT18
cells (Fig. 4B). These data suggest that there are two indepen-
dent pools of RelA/NF-B complexes in these cells: a basal
pool and an inducible, cytoplasmic pool. The data clearly show
that the induction of the inducible pool to the nucleus is re-
quired for the nucleolar translocation of basal complexes.
Because the accumulation of several proteins within the
nucleolus is transcription dependent, we next determined
whether the nucleolar localization of RelA was modified by
actinomycin D. Using immunocytochemistry and with nucleo-
lin as a nucleolar marker, we found that the treatment of cells
with aspirin in the presence of actinomycin D resulted in RelA
staining throughout the nucleoplasm, with exclusion from the
remaining nucleoli (Fig. 4C). Treatment with aspirin in the
presence of cycloheximide also prevented translocation of
RelA to the nucleolus, causing it to accumulate in the nucle-
oplasm (Fig. 4C). Similar results were obtained when SW480
cells were serum deprived in the presence of actinomycin D or
cycloheximide, in that the nucleolar translocation of RelA was
abrogated (Fig. 4D). These data confirm that aspirin and se-
rum deprivation induce the translocation of RelA from the
cytoplasm to the nucleoplasm and suggest that synthesis of one
or more proteins is required for RelA translocation from the
nucleoplasm to the nucleolus.
Identification of a RelA nucleolar localization domain. To
further understand the mechanism by which RelA translocates
from the nucleoplasm to the nucleolus, we constructed a series
of deletion mutants of RelA as GFP fusion proteins (Fig. 5A).
The respective deletions were transiently transfected into
SW480 cells and their subcellular distributions monitored in
individual live cells. Prior to treatment, WT and deleted pro-
teins were distributed within the cell as expected from pub-
lished data (18). RelA containing the region between amino
acids 1 and 311 (RelA 1-311) was predominantly nuclear,
which has previously been described for RelA mutants lacking
the nuclear export signal at the C terminus (Fig. 5B). RelA
WT, 105-511, and 50-511 were localized within the cytoplasm,
with a small amount of nucleoplasmic staining, while RelA
290-511 was distributed throughout the cell (Fig. 5B). Follow-
ing exposure to aspirin, there was a decrease in cytoplasmic,
and a corresponding increase in nuclear, levels of RelA in all
cases, confirming the activation of the NF-B pathway. How-
ever, there were distinct differences in the nuclear distributions
of the GFP-tagged proteins, dependent upon the presence of
the N terminus of the protein. We found that RelA WT and
1-311 accumulated in the nucleolus in response to aspirin (Fig.
5B). In contrast, mutants lacking the N-terminal 50 amino
acids of the protein accumulated in the nucleoplasm and were
excluded from the nucleolus (Fig. 5B). These data suggest that
amino acids 1 to 50 of RelA contain the domain required for
nucleolar localization. Aspirin had no effect on the cellular
distribution of the GFP control (Fig. 5B).
For several proteins, it has been demonstrated that nucleo-
lar localization is dependent upon the presence of a NoLS (19,
47). Sequence alignment of amino acids 1 to 50 of RelA with
other published sequences known to mediate nucleolar local-
ization revealed a potential NoLS at positions 27 to 38 of the
protein. In particular, a motif (PKQR) at amino acids 27 to 30
appeared to be conserved among these sequences (Fig. 5C).
Using site-directed mutagenesis, we generated a GFP-tagged
RelA construct with a deletion of this motif (RelA27-30). As
shown in Fig. 5D, the RelA27-30 mutant did not translocate
to the nucleolus and consequently accumulated in the nucleo-
plasm.
RelA function is known to be modulated by acetylation (9)
and ubiquitination (40), which both occur on lysine (K) resi-
dues. Since the motif we identified to be important for the
nucleolar localization of RelA contained a lysine residue
(K28), we postulated that this response may involve one of
these modifications. However, we found that full-length RelA
with a single K-to-R (arginine) mutation at residue 28 (GFP-
RelA K28/R), which precludes acetylation or ubiquitination at
this site, translocated to the nucleolus in response to aspirin in
a fashion similar to that of the WT protein (Fig. 5E). This
result is in keeping with aa 27 to 30 of RelA acting as an NoLS,
since K and R residues are interchangeable within these motifs
(47). Taken together, these data strongly suggest that RelA is
actively transported from the nucleoplasm to the nucleolus and
that there is a nucleolar localization domain located at the N
terminus of the protein.
Nucleolar translocation of RelA is paralleled by a decrease
in NF-B-driven transcription. Having established that RelA
accumulates in the nucleolus in response to specific proapo-
ptotic NF-B stimuli, we wished to determine whether this
compartmentalization regulates nuclear NF-B activity and
apoptosis. To do this, we initially examined the effect of aspirin
on NF-B transcriptional activity using the HIV-LTR and 3en-
hancer-CON-A (3x B ConA-luc) NF-B-dependent lucif-
erase reporter plasmids. We found that aspirin induced a sig-
nificant decrease in basal NF-B-driven luciferase activity in
FIG. 5. Aspirin-induced nucleolar translocation of RelA requires an N-terminal nucleolar localization motif. (A) Deletions of RelA were
cloned into the PEGFP-C1 vector. RHD, Rel homology domain; NLS, nuclear localization signal; NES, nuclear export signal. The distributions
of the respective deletions are shown. , nucleolar; , nucleoplasmic. (B) Deleting the N-terminal 50 aa of RelA blocks nucleolar translocation
of the protein. SW480 cells were transfected with the specified GFP-tagged RelA expression constructs 24 h prior to treatment with 0 or 5 mM
aspirin. The cellular distribution of GFP-tagged protein was determined in live/adherent cells using an Axiovert 100 inverted fluorescent
microscope (magnification, 40). (C) The N terminus of RelA contains a potential NoLS. Amino acids 1 to 50 of RelA were aligned to other
published nucleolar localization signals (19, 47) using ClustalW. Each shaded area indicates a potential NoLS. (D) Deletion of aa 27 to 30 inhibits
nucleolar translocation of RelA. SW480 cells were transfected with the RelA 27-30 expression construct 24 h prior to treatment with 0 or 5 mM
aspirin. The cellular distribution of GFP-tagged protein was determined as described above. (E) Nucleolar localization of RelA does not involve
posttranslational modification of lysine (K) 28. SW480 cells were transfected with a full-length GFP-RelA expression construct containing a K-to-R
(arginine) mutation at residue 28 (RelA K28/R). The cellular distribution of this mutant was determined following aspirin treatment as described
above.
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FIG. 6. Nucleolar localization of RelA is paralleled by a decrease in NF-B-driven transcription. (A and B) Pharmacologically relevant doses
of aspirin repress NF-B transcriptional activity. SW480 cells were transfected with 6 g of wild-type (3x B ConA and HIV-LTR) NF-B-
dependent luciferase reporter constructs or with equivalent plasmids with B sites deleted (HIVB, ConAB) along with 3 g of pCMV
control plasmid. Twenty-four hours after transfection, cells were either unstimulated or stimulated with aspirin for a further 16 (3 to 10 mM) or
72 (0 to 2 mM) hours. Results were normalized using -galactosidase activity and are presented as the percentages of relative luciferase activity
compared to basal levels (untreated controls). (C) Aspirin induces apoptosis. Annexin V-FITC apoptosis assays were performed on aspirin-treated
(0 to 2 mM, 72 h) SW480 cells. Apoptotic cells were visualized using fluorescent microscopy, and the percentages of apoptotic cells within the total
cell populations were calculated. (D) Aspirin-induced apoptosis is not enhanced in low-serum conditions. Annexin V-FITC apoptosis assays were
performed on SW480 cells treated with aspirin (Asp.) (0 or 0.5 mm, 72 h) in low-serum (0.5% FCS) or normal-serum (10% FCS) conditions.
(E) Aspirin induces degradation of IB. Immunoblot showing cytoplasmic levels of IB and control protein (Cu/ZnSOD) in SW480 cells treated
with 0 to 2 mM aspirin for 72 h or 3 to 10 mM aspirin for 16 h. (F) Aspirin induces nuclear translocation of RelA/NF-B complexes. SW480 cells
were either unstimulated () or stimulated () with aspirin (5 mM for 16 h) or TNF (10 ng/ml, 1 h). Nuclear extracts were prepared and analyzed
by EMSAs using a B oligonucleotide. The incubation of extracts with the RelA antibody prior to the assay resulted in a complete shift of the
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colon cancer cells (Fig. 6A and B). This decrease was apparent
at 500 M and was dependent upon both aspirin concentration
and the number of B sites in the luciferase construct (Fig. 6A
and B). Furthermore, this decrease in NF-B transcriptional
activity paralleled the dose-dependent increase in the number
of cells showing nucleolar foci of RelA that we observed (Fig.
1A). Aspirin (at the highest concentration used [10 mM]) had
a minimal effect on the transcription from control plasmids
with deleted B sites compared to wild-type equivalents (Fig.
6A and B), demonstrating that the observed decrease is de-
pendent upon NF-B. Using annexin V-FITC staining of cell
surface phosphatidylserine residues, we demonstrated that as-
pirin effects on the nuclear distribution of RelA and NF-B
transcriptional activity were also paralleled by the apoptosis of
colon cancer cells (Fig. 6C). In the above experiments, cells
were treated with aspirin and other NF-B stimuli in condi-
tions of low serum (0.5% FCS). Since total serum deprivation
(0% FCS) had an effect similar to that of aspirin on RelA
nuclear distribution (Fig. 3C), we considered whether the
NF-B and apoptotic responses to low-dose aspirin were en-
hanced by low-serum conditions. However, we found no dif-
ference in aspirin response when treatment occurred in 0.5%
and 10% FCS media in terms of the nucleolar translocation of
RelA, decreased NF-B-driven transcription, and apoptosis
(Fig. 6D and data not shown).
Aspirin has previously been shown to inhibit TNF-induced
NF-B-driven transcription, and this has been attributed to the
inhibition of IKK activity/degradation of IB (23, 49, 50). To
eliminate the possibility that the decrease in NF-B-driven
transcription we observed in response to this particular agent is
caused by the inhibition of IB degradation, we further exam-
ined the aspirin-mediated activation of the NF-B pathway.
Western blot analysis of cytoplasmic extracts and EMSAs per-
formed on nuclear extracts demonstrated reduced levels of
cytoplasmic IB (Fig. 6E) and a strong induction of nuclear
NF-B (Fig. 6F) in response to aspirin. The aspirin-induced
NF-B complex had the same mobility as that induced by TNF,
and supershift EMSAs confirmed that it consisted predomi-
nantly of the RelA transcriptional activator (Fig. 6F). Since the
IB promoter is recognized to be a target of NF-B, we used
the MG132 proteosome inhibitor to confirm that the reduction
in cytoplasmic IB levels was mediated by the proteosomal
degradation of the protein (42; also data not shown). The
phosphorylation of RelA at serine 536 is critical for the full
activation of the protein (8). Western blot analysis, using
phospho 536-specific antibodies, indicated that the aspirin-
induced phosphorylation of RelA at this residue was compa-
rable to that seen following treatment with TNF (Fig. 6G).
These data confirm that the observed decrease in NF-B tran-
scriptional activity in response to aspirin is associated with
IB degradation and the nuclear translocation of RelA/NF-B
complexes, thereby providing strong evidence against the di-
rect inhibition of IKK activity as the underlying cause of the
aspirin effects. The upstream mechanisms by which aspirin
activates the NF-B pathway are currently subject to ongoing
investigation in our lab and are outside the focus of this report.
Since we observed constitutive nuclear NF-B activity in
colon cancer cells, which decreased upon treatment with aspi-
rin, we postulated that aspirin may (directly or indirectly) in-
duce the repression of NF-B-driven transcription within the
nucleus independently of its effects on cytoplasmic NF-B and
the nuclear distribution of RelA. Therefore, we wished to test
whether, like nucleolar accumulation of RelA, the cytoplasmic-
to-nuclear translocation of NF-B complexes was also required
for this reduction in NF-B-driven transcription. We found
that aspirin mediated a 5.8-fold decrease in NF-B transcrip-
tional activity in parental HRT 18 cells, compared to a 1.9-fold
decrease in cells expressing dominant-negative IB (IBSR)
(Fig. 6H). This diminished response was independent of basal
transcription because, consistent with the basal nucleoplasmic
staining for RelA (Fig. 4B), the IBSR clones showed levels of
basal NF-B driven transcription similar to those of their pa-
rental counterparts (data not shown). These data indicate that
the repression of NF-B-driven transcription is also a conse-
quence of IB degradation and the nuclear translocation of
NF-B complexes.
On the basis of our observations so far, we hypothesized that
the stimulation of the NF-B pathway by particular signals
promotes apoptosis by inducing the nucleolar sequestration of
RelA and the inhibition of NF-B-driven transcription. Next,
we undertook a series of experiments to determine whether the
nucleolar translocation of RelA is causally involved in the
reduction of B-driven transcription and the induction of ap-
optosis.
Temporal relationship of IB degradation, nucleolar accu-
mulation of RelA, repression of NF-B activity, and apoptosis.
As a first step, we examined the kinetics of these responses. We
found that aspirin-induced IB degradation occurred within 2
hours of treatment (Fig. 7A) and was associated with an initial
nucleoplasmic accumulation of RelA (Fig. 7B). This nucleo-
plasmic RelA had no effect on NF-B-driven transcription.
The percentage of cells showing nucleolar RelA increased
progressively to a peak at 5 to 8 h (Fig. 7B and C), which
coincided with the onset of NF-B transcriptional repression
(Fig. 7D). The nucleolar accumulation of RelA was not a
consequence of cell death, since apoptosis, as determined by
caspase-3 cleavage (Fig. 7E) and annexin V staining (Fig. 7F),
was not observed until 16 h after aspirin treatment.
Inhibiting nucleolar translocation of RelA inhibits the as-
pirin-induced decrease in NF-B transcriptional activity and
aspirin-induced complex, confirming the complex consists predominantly of this component. The arrow indicates the supershifted band. The
aspirin-induced complex was also competed out with 100 molar excess of unlabeled B oligonucleotide. (G) Phosphorylation of RelA serine 536
in response to aspirin. SW480 cells were treated with aspirin (0 to 5 mM, 16 h) or TNF (10 ng, 1 h), and then immunoblot analysis was performed
on total-cell extract. Blots were initially probed with a RelA phospho 536-specific antibody (Calbiochem) and then stripped and reprobed for total
RelA. (H) Expression of superrepressor IB blocks aspirin-mediated repression of NF-B transcriptional activity. HRT18 parental cells and clones
IBSR1 and SR28 (which are resistant to aspirin-induced nuclear and nucleolar translocation of RelA) were transfected with the B (HIV-LTR)
and pCMV- reporter constructs prior to a 16-h treatment with 0 or 5 mM aspirin. Results shown are normalized using -galactosidase activity
and are presented as described above.
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FIG. 7. IB degradation, nucleolar translocation of RelA, repression of NF-B transcription, and apoptosis occur sequentially. (A) IB
degradation occurs 2 to 5 h after stimulation with aspirin. Cells were treated with aspirin (10 mM) for 0 to 16 h, and then cytoplasmic IB and
control protein (CU/Zn SOD) levels were determined using Western blot analysis. (B and C) Nucleolar accumulation of RelA (p65) is apparent
5 to 8 h after aspirin stimulation. Immunocytochemistry was performed on SW480 cells treated as described above. DAPI staining depicts nuclei.
Nucleoli are stained with nucleolin. Bars, 10 m. The percentage of cells in the population showing nucleolar RelA (p65) was quantified. Data
are the means of at least three experiments (
 SE). (D) Decreased NF-B-driven transcription occurs concurrently with nucleolar accumulation
of RelA. SW480 cells were transfected with the NF-B dependent 3xB ConA-luc and the control pCMV reporter constructs. Twenty-four hours
after transfection, cells were treated as described above. Values are presented as the percentages of luciferase activity at time zero and are the
means (
 SE) of three independent experiments after -galactosidase normalization. (E) Aspirin-induced caspase-3 cleavage occurs 16 h after
stimulation. SW480 cells were treated as described above and levels of uncleaved caspase-3 determined by Western blot analysis performed on
cytoplasmic extracts. (F) Percentages of SW480 cells undergoing apoptosis, as determined by annexin V staining, following aspirin treatment as
described above.
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apoptosis. We next utilized the RelA NoLS deletion mutant
(RelA 27-30) to directly test whether the nucleolar localiza-
tion of RelA is causally involved in the repression of NF-B-
driven transcription and apoptotic cell death. We determined
whether exogenously expressing RelA27-30 modulates the
distribution of endogenous protein. Using RelA immunocyto-
chemistry performed on transfected SW480 cells, we found
that, as expected, cells expressing RelA WT showed nuclear
and nucleolar localization of RelA in response to aspirin (Fig.
8A). However, in cultures expressing RelA 27-30, which lacks
the N-terminal NoLS, there was no nucleolar translocation of
either mutant or endogenous protein in transfected cells. In
contrast, adjacent nontransfected cells showed aspirin-medi-
ated nucleolar accumulation of endogenous protein (Fig. 8A).
These results suggest that mutants which are unable to trans-
locate to the nucleolus act in a dominant-negative fashion to
block the nucleolar translocation of endogenous RelA.
Using the dominant-negative NoLS deletion mutant, we ini-
tially examined the effects of inhibiting the nucleolar seques-
tration of RelA on the aspirin-induced repression of NF-B-
driven transcription. SW480 cells were transiently transfected
with the GFP-RelA WT or 27-30 expression constructs along
with the 3x B ConA-Luc reporter vector. Following aspirin
treatment, RelA-expressing cells were isolated from nontrans-
fected cells using a fluorescence-activated cell sorter. The
NF-B reporter activity was then assayed in the GFP-RelA
WT/27-30-expressing population. Our data show that the as-
pirin-induced repression of NF-B transcriptional activity was
substantially abrogated in RelA 27-30-expressing cells (in
which nucleolar translocation had been blocked) compared to
those expressing the wild-type protein (RelA-WT) (Fig. 8B).
The differences in responses could not be accounted for by
differing basal levels of NF-B-driven transcription, because
these were comparable for cells expressing RelA-WT (12.3 
106; SE, 3.2  106) and RelA 27-30 (11  106; SE, 1.55 
106). The levels of expression of GFP-tagged protein were also
comparable for wild-type and mutated RelA and remained
unchanged by aspirin treatment (Fig. 8C).
To determine whether inhibiting RelA nucleolar transloca-
tion blocks the aspirin-induced growth inhibition of cancer
cells, we initially examined aspirin effects on the viability of
SW480 cell cultures transfected with GFP-RelA WT, K28/R,
or the construct with the deletion of the NoLS, RelA 27-30.
Aspirin induced a marked reduction in the number of viable
colorectal cancer cells in cultures expressing GFP alone, GFP-
RelA WT, or K28/R. However, this effect was inhibited in
cultures expressing RelA 27-30 (data not shown). Phase-
contrast microscopy confirmed the extensive cell death in cul-
tures expressing RelA WT and RelA K28/R, which translocate
to the nucleolus, while aspirin had a minimal effect on the
numbers and morphology of cells within cultures expressing
RelA 27-30, which is excluded from the nucleolus (Fig. 8E).
Transfection efficiencies were similar for all expression vectors.
Next, we investigated the effects of expressing WT and mu-
tated RelA on aspirin-induced apoptosis. Use of a biotin-an-
nexin V assay, along with a streptavidin-Texas Red conjugate,
allowed us to distinguish apoptotic and transfected cells and
thus determine the percentages of cells undergoing apoptosis
specifically in the transfected and nontransfected cell popula-
tions. We found that aspirin-induced apoptosis was inhibited in
cells expressing RelA-27-30 (Fig. 8F). In contrast, compared
to the expression of GFP alone, apoptosis was enhanced in
cells expressing RelA-WT and K28/R. Aspirin-induced apo-
ptosis was observed to similar extents in all nontransfected
cells (data not shown).
Amino acids 27 to 30 of RelA are essential for aspirin-
induced repression of NF-B-driven transcription and apo-
ptosis. To definitively establish whether the nucleolar targeting
of RelA is absolutely required for aspirin effects on NF-B-
driven transcription and apoptosis, we utilized rela null MEFs
transfected with either GFP, GFP-RelAWT, or -RelA27-30.
Aspirin effects on the localization of these GFP-tagged pro-
teins were similar to those observed in colorectal cancer cell
lines; both RelA WT and 27-30 translocated from the cyto-
plasm to the nucleus in response to aspirin. However, only
RelA WT was able to translocate from the nucleoplasm to the
nucleolus (Fig. 9A). The deletion of amino acids 27 to 30
abrogated this response, causing RelA to accumulate in the
nucleoplasm (Fig. 9A). Aspirin had no effect on the localiza-
tion of GFP alone (data not shown). Next, we examined aspirin
effects on NF-B-driven transcription in these cells using the
3x B ConA-luc NF-B-dependent reporter plasmid. We
found that 2 to 5 h after aspirin (10 mM) treatment, there was
a twofold repression in NF-B transcriptional activity in cells
expressing GFP-RelA WT (Fig. 9B). In marked contrast, there
was a twofold activation of NF-B-driven transcription in cells
expressing GFP-RelA 27-30. WT and 27-30 RelA activated
NF-B-driven transcription in response to TNF to comparable
degrees (Fig. 9C). Neither aspirin nor TNF had any effect on
the equivalent NF-B reporter plasmid with B sites deleted
(data not shown), confirming the specificity of these effects.
Western blot analysis confirmed that WT and 27-30 RelA
proteins were expressed at similar levels before and after as-
pirin treatment (Fig. 9D) and that the MEFs were indeed null
for endogenous rela (data not shown). These data establish the
crucial importance of aa 27 to 30 relative to aspirin effects on
NF-B transcriptional activity and also demonstrate that the
differences in aspirin responses between the wild-type protein
and the protein with the deletion of NoLS do not reflect a
general difference in their DNA binding and transactivating
potentials.
We next used annexin V assays to investigate the apoptotic
response of these cells to aspirin. We found that nontrans-
fected rela null MEFs were resistant to aspirin-induced apo-
ptosis but underwent extensive apoptosis in response to TNF
(data not shown). However, when they were transfected with
WT RelA, there was a decrease in the number of viable cells
(data not shown) and a substantial increase in apoptosis in
response to aspirin (Fig. 9E). This apoptotic response was
blocked in cells expressing RelA with a deletion of the NoLS
and in cells expressing GFP alone (Fig. 9E). These data con-
firm the importance of RelA, and in particular the NoLS of
RelA (aa 27 to 30), in aspirin-induced apoptosis.
Inhibiting the nucleolar translocation of RelA inhibits UV-
C-induced apoptosis. UV-C radiation is a recognized proapo-
ptotic stimulus of NF-B (5, 22) that, as we have shown, also
targets RelA to the nucleolus (Fig. 3C). Having established the
importance of the nucleolar translocation of RelA in aspirin-
induced apoptosis, we next determined whether blocking this
pathway also inhibited the proapoptotic effects of UV-C. First,
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we needed to know whether the region from aa 27 to 30 was
involved in the UV-C-induced nucleolar translocation of RelA.
SW480 cells were transfected with GFP, GFP-RelA WT, or
GFP-RelA27-30 and then mock or UV-C (40 J/m2) irradi-
ated. Live-cell imaging was used to determine UV-C effects on
the nuclear distribution of GFP-tagged proteins. Figure 10A
demonstrates that GFP-RelA WT, in a manner similar to the
aspirin response, accumulates in the nucleolus after UV-C
treatment and that GFP-RelA27-30 is excluded from the
nucleolus, accumulating in the nucleoplasm. RelA WT and
27-30 remained cytoplasmic in all mock-irradiated cells, and
UV-C had no effect on the distribution of GFP alone (data not
shown). These data confirm the importance of aa 27 to 30 for
the nucleolar targeting of RelA.
Next, we examined the effects of expressing GFP-RelA WT
and 27-30 on UV-C-induced changes in cell viability. We
found that UV-C (40 J/m2) irradiation caused a marked re-
duction in the number of viable SW480 cells in cultures ex-
pressing GFP alone or GFP-RelAWT (data not shown).
However, these effects were abrogated in cultures expres-
sing RelA27-30. Phase-contrast microscopy confirmed that
UV-C mediates extensive cell loss in cultures expressing
GFP-RelAWT while having a minimal effect on the numbers
or morphology of cells in cultures expressing RelA27-30
(Fig. 10B). To confirm that the observed cell loss was me-
diated by apoptosis and that 27-30 RelA blocked this ap-
optosis, we used biotin-conjugated annexin V apoptosis as-
says, along with streptavidin-linked Texas Red, to determine
the percentage of transfected cells undergoing apoptosis.
Figure 10D demonstrates that there are twofold increases in
the percentages of cells undergoing apoptosis in cells ex-
pressing GFP alone or GFP-RelAWT in response to UV-C.
However, this effect is blocked by the expression of the
NoLS deletion mutant, RelA27-30. Taken together with
data presented above, these data provide compelling evi-
dence that the nucleolar targeting of RelA is involved in the
regulation of NF-B and apoptosis in response to particular
proapoptotic NF-B stimuli.
DISCUSSION
Mechanisms that regulate NF-B activity within the nucleus
are critical for determining the effect that stimulating this path-
way has on downstream target genes and thus on the growth
and death of cells (8). Here we demonstrated, using immuno-
cytochemistry to detect endogenous protein, live-cell imaging,
and biochemical assays, that the RelA component of NF-B
localizes to the nucleolus in response to aspirin and other
proapoptotic NF-B stimuli. Our analysis of the function of
this subnuclear compartmentalization suggests a model for the
regulation of nuclear NF-B activity and the modulation of
apoptosis (Fig. 11).
In addition to ribogenesis, it is increasingly apparent that the
nucleolus has an important role in regulating cell cycle transi-
tion, cell proliferation, and apoptosis through the sequestra-
tion of key cell cycle and transcription factors (7, 38). Examples
include the NF-B coactivator E2F-1 (26), hypoxia-inducible
factor-1 (15), and p53 (37, 47). Here we identify an N-terminal
motif of the RelA component of NF-B that targets the pro-
tein to the nucleolus. We demonstrate both in colorectal can-
cer cell lines and in mouse embryo fibroblasts that this nucle-
olar localization motif is required for aspirin-induced
apoptosis. Furthermore, using RelA with a deletion of this
motif, we demonstrate that the nucleolar translocation of RelA
is required for UV-C induced apoptosis. Therefore, we con-
clude that the nucleolus also plays a role in regulating NF-B
effects on cell growth and death.
Our model suggests that the mechanism by which the nucle-
olar targeting of RelA mediates apoptosis is by sequestering
RelA away from target promoters, thus causing a decrease in
the transcription of NF-B-dependent, antiapoptotic genes.
Our conclusion that the compartmentalization of RelA within
the nucleolus modulates NF-B-driven transcription is based
on the following observations. First, dose-response (Fig. 1 and
6) and kinetic (Fig. 7) studies show a relationship between the
nucleolar accumulation of RelA and a reduction in NF-B-
driven transcription. Second, cell fractionation studies indicate
that the decrease in the basal pool of RelA in the nucleoplasm
(where target promoters are located) and the corresponding
FIG. 8. Inhibiting nucleolar translocation of RelA blocks aspirin-induced repression of NF-B-driven transcription and apoptosis. (A) Exo-
genally expressed RelA 27-30 blocks nucleolar translocation of endogenous RelA. Immunomicrographs (magnification, 63) showing localiza-
tion of all (RelA) or GFP-tagged (GFP) RelA in SW480 cells transfected with GFP-WT (a to f) or 27-30 (g to o) RelA and then treated with
0 () or 5 () mM aspirin (Asp) for 16 h. Panels m to o show RelA in nontransfected cells (confirmed by the lack of a GFP signal in panel n)
adjacent to the RelA 27-30-transfected cells shown in panels j to l. Blue depicts DAPI staining of DNA. Bars, 10 m. (B) Deletion of amino acids
27 to 30 of RelA inhibits aspirin effects on NF-B-driven transcription. SW480 cells were transfected with the GFP-RelA WT or 27-30 expression
vector, along with the 3x B ConA-luc reporter plasmid. Following aspirin treatment (5 mM, 16 h), GFP-tagged cells were isolated using a
fluorescence-activated cell sorter. Relative luciferase activity was calculated as the level of luciferase activity per GFP-expressing cell in the
population. Results are presented as the reduction in relative luciferase activity compared to untreated controls and are the means of at least three
experiments (
 SE). The basal (12.3  106; SE, 3.2  106) levels of luciferase activity were comparable between cells expressing WT-RelA and
those expressing 27-30-RelA (11  106; SE, 1.55  106). (C) Immunoblots showing GFP and control protein (Actin) expression levels in cells
transfected with GFP-tagged WT or 27-30 RelA before and after aspirin (5 mM, 16 h) treatment. (D) Deletion of amino acids 27 to 30 of RelA
inhibits aspirin effects on cell viability. SW480 cells were transfected with the indicated RelA expression vectors 24 h prior to stimulation with
aspirin (5 mM, 16 h). Phase-contrast images of randomly selected fields are shown (magnification, 10). (E) Deletion of amino acids 27 to 30 of
RelA inhibits aspirin-induced apoptosis. SW480 cells were transfected with the specified vectors and treated with aspirin as described above.
Annexin V-biotin staining, with a Texas Red-streptavidin conjugate, was used to identify apoptotic cells. The percentages of cells expressing
GFP-tagged RelA undergoing apoptosis were determined by fluorescent microscopy in at least 250 transfected cells for each sample. The number
of apoptotic cells in the nontransfected population was also determined. The results are the means of at least three independent experiments 
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FIG. 9. Amino acids 27 to 30 of RelA are essential for aspirin effects on NF-B transcriptional activity and apoptosis in rela null MEFs. (A) rela
null MEFs were transfected with 3 g of GFP-RelA WT or -RelA27-30. Cells were either unstimulated (Asp.) or stimulated for 5 h with aspirin
(10 mM) (Asp.), and then the localization of GFP-tagged proteins was analyzed in fixed cells using fluorescent microscopy (magnification, 63).
(B and C) rela null MEFs were transfected with the above plasmids along with 3 g of 3xB ConA NF-B dependent luciferase reporter constructs
and 3 g of pCMV control plasmid. Twenty-four hours after transfection, cells were either unstimulated, (B) stimulated with aspirin (10 mM)
for the times specified, or (C) stimulated with TNF (10 ng/ml) for 5 h. Results were normalized using -galactosidase activity and are presented
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increase in nucleolar RelA in response to aspirin are associ-
ated with a reduction in NF-B transcriptional activity (Fig. 2C
and 6A). Finally, and most convincingly, blocking the nucleolar
localization of RelA with the dominant-negative NoLS dele-
tion mutant (RelA 27-30) reversed the effects of aspirin on
basal NF-B transcriptional activity in each of the cellular
models studied (Fig. 8 and 9).
In order to be fully active, nuclear RelA is required to
undergo a number of posttranslational modifications, princi-
pally phosphorylation and acetylation (8). Therefore, we con-
sidered the possibility that the reductions in NF-B-driven
transcription and apoptosis were caused by the induction of
transcriptionally inactive RelA rather than by nucleolar trans-
location of basal RelA per se. However, the NoLS deletion
mutant of RelA had the same established phosphorylation and
acetylation sites as the wild-type GFP-tagged protein. How-
ever, the RelA with the deletion activated, rather than re-
pressed, NF-B-driven transcription in response to aspirin and
activated NF-B transcriptional activity in response to TNF to
a level comparable with that of wild-type protein. Further-
more, mutation of the lysine residue within this motif, which is
a potential site for acetylation, did not affect the outcome of
the aspirin treatment. Our data suggest that a cofactor(s) is
required for the nucleolar translocation of RelA. Therefore,
we also considered that it is the binding of this cofactor to basal
RelA that causes it to become actively repressive at promoter
sites, inducing apoptosis. However, our kinetic studies show
that at 2 h, when aspirin-induced RelA is nucleoplasmic, there
is no change in NF-B transcriptional activity (Fig. 7). It is only
during RelA nucleolar translocation (at 5 to 8 h) that aspirin
mediates a decrease in NF-B-driven transcription.
We did consider the possibility that the nucleolar seques-
tration of RelA and the reduction in NF-B transcriptional
activity were consequences rather than the causes of cell
death. However, we observed extensive apoptosis of SW480
colon cancer cells in response to the activator of NF-B-
driven transcription, TRAIL (42, 51; also data not shown), but
RelA was nucleoplasmic and remained excluded from the nu-
cleolus (Fig. 3). Furthermore, our kinetic studies clearly dem-
onstrated that aspirin-induced nucleolar localization of RelA
and reduction in NF-B transcriptional activity occurred be-
fore caspase-3 cleavage and also before any detectable increase
in apoptotic cell populations. Finally, and most convincingly,
aspirin- and UV-C-induced apoptosis was inhibited in cells
expressing the RelA27-30 mutant (Fig. 8, 9, and 10). There-
fore, it is very unlikely that the observed responses are a result
of apoptosis. Taken together, these data provide convincing
evidence that diverting RelA from its gene targets in the nu-
cleoplasm to the nucleolus can regulate nuclear NF-B tran-
scriptional activity and mediate apoptosis. These novel findings
contribute to the growing literature on the importance of the
nucleolus as a regulatory structure.
We observed nucleolar translocation of RelA in response to
UV-C radiation and demonstrated that deleting the NoLS of
RelA blocked UV-C-induced apoptosis. Our model would sug-
gest that the mechanism for this apoptosis is a decrease in the
transcription of NF-B-dependent, antiapoptotic genes. This is
of particular interest because Campbell et al. (5) recently dem-
onstrated that UV-C-induced nuclear translocation of RelA/
NF-B complexes mediated the repression of the antiapoptotic
Bcl-xl gene. However, they observed increased binding of RelA
at the Bcl-xl promoter in response to UV-C and proposed a
mechanism of active repression, whereby basal NF-B com-
plexes are converted from active to repressive. This is in con-
trast to the model that we propose, whereby induced RelA
relocalizes basal RelA/NF-B complexes to the nucleolus, se-
questering them away from target promoters. Because of dif-
ferences in experimental setups and outcomes, it is currently
difficult to reconcile the differences between these two models.
However, it is possible that in the complexities of the subcel-
lular environment, both models might apply.
The degradation of IB and the cytoplasmic-to-nuclear
translocation of NF-B/RelA complexes were absolutely re-
quired for nucleolar translocation of both induced and basal
RelA (Fig. 4). Therefore, we propose that the NF-B com-
plexes induced by aspirin, UV-C radiation, and serum with-
drawal recruit a specific cofactor(s) to the basal, promoter-
bound complexes, which then transport all nuclear RelA to the
nucleolus. This is supported by the kinetic studies demonstrat-
ing that induced RelA distributes throughout the nucleoplasm
in basal complexes (Fig. 7) prior to localization in the nucle-
olus. Furthermore, in the absence of protein synthesis, RelA
accumulates in the nucleoplasm in response to aspirin and
serum deprivation, suggesting that an additional cofactor(s) is
required for transport to the nucleolus. Although we do not
know the nature of this cofactor at present, it is of particular
interest that RelA has recently been found to interact with the
nucleolar proteins NFBP (43) and nucleophosmin/B23 (12).
Since the increased transcription of nucleophosmin has been
identified as an early gene response to specific external stimuli
(48), this is a particularly strong candidate. Another potential
candidate is the nucleolar protein p14ARF, which has recently
been shown to interact with RelA and inhibit NF-B-driven
transcription (32). We show here and elsewhere (42, 51) that
NF-B is rapidly induced by TNF and TRAIL and localizes in
the nucleoplasm, whereas RelA localizes to the nucleolus in
response to aspirin, serum deprivation, and UV-C radiation,
which all induce NF-B with much slower kinetics (5, 16, 42).
It therefore seems possible that the kinetics of NF-B induc-
tion determines the recruitment of the specific cofactors re-
as the percentages of relative luciferase activity compared to basal levels (untreated controls). The basal luciferase values for cells expressing
GFP-RelAWT (26.36  106; SE, 8.6  106) and those expressing GFP-RelA 27-30 (17.15  106; SE, 5.9  106) were not significantly different.
(D) Western blot analysis showing expression levels of GFP-RelA WT and 27-30 in aspirin-treated and untreated rela null MEFs. (E) The NoLS
of RelA is required for aspirin-induced apoptosis. SW480 cells were transfected with the specified vectors and treated with aspirin as shown.
Annexin V-biotin staining, with a Texas Red-streptavidin conjugate, was used to identify apoptotic cells. The percentages of cells expressing
GFP-tagged RelA undergoing apoptosis were determined by fluorescent microscopy in at least 250 transfected cells for each sample. The results
are the means of at least three independent experiments 
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sponsible for the subnuclear distribution of RelA and the
downstream effects on cell growth and death. Defining the
mechanism that determines the subnuclear distribution of
translocated NF-B complexes could have considerable rele-
vance to the development of chemotherapeutic agents and also
provide further insight into the complexities of the NF-B
pathway.
Our finding that aspirin activates the NF-B pathway would
appear to question a number of studies demonstrating that
nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit the ac-
FIG. 10. Nucleolar localization of RelA is required for UV-C-induced apoptosis. (A) Deleting aa 27 to 30 inhibits UV-C-induced nucleolar
translocation of RelA. SW480 cells were transfected with 6 g of GFP, GFP-RelA WT, or RelA 27-30 24 h prior to UV-C treatment (40 J/m2). The
localization of GFP-tagged proteins was determined in live cells using an Axiovert 100 inverted fluorescent microscope (magnification, 40) 8 h after
treatment. (B) Expression of RelA 27-30 inhibits UV-C effects on cell viability. SW480 cells were transfected and UV-C treated as described above.
Phase-contrast images (magnification, 20) taken of randomly selected fields 24 h after treatment are shown. (C) Expression of RelA 27-30 inhibits
UV-C effects on apoptosis. Annexin V apoptosis assays were performed on SW480 cells transfected with the specified GFP-tagged vectors 24 h after
UV-C (40 J/m2) treatment. The percentages of cells expressing GFP-tagged protein undergoing apoptosis were determined by fluorescent microscopy
in at least 250 transfected cells for each sample. The results are the means of at least three independent experiments 
 standard errors.
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tivation of NF-B (23, 49, 50). However, these studies exam-
ined only the very short-term effects of NSAIDs on the cyto-
kine-induced activation of NF-B. In the present study, we
investigated the longer-term effects of aspirin alone on NF-B
signaling. Since aspirin mediates the apoptosis of cancer cells
in vitro in the absence of additional cytokines, these experi-
mental conditions are most relevant to the proapoptotic prop-
erties of the agent. The NSAID celecoxib (28) and the COX-
2-specific inhibitor NS-398 (41) have also been shown to
induce the degradation of IB and the nuclear translocation of
NF-B in the absence of additional NF-B stimulators.
Whether activation of the NF-B pathway is a primary effect of
aspirin or secondary to its effect on another cellular pathway
has yet to be established. However, we have demonstrated that
nuclear and nucleolar translocations of RelA are absolutely
required for aspirin-mediated apoptosis, indicating that it is
this pathway that is ultimately responsible for the proapoptotic
effects of the agent.
The constitutive activity of NF-B has been shown to con-
tribute to carcinogenesis in a number of cancer types (17).
Therefore, in identifying a cellular mechanism to repress NF-
B-driven transcription, the results presented here may have
general relevance to future rational drug design for cancer
therapy. Furthermore, the mechanism of the apoptotic re-
sponse induced by aspirin has particular relevance to under-
standing the mechanism by which NSAIDs protect against
cancer. Gaining further understanding of how RelA is seques-
tered in the nucleolus may allow the design of small molecules
which specifically target RelA to this compartment.
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